ENLIVEN THERAPEUTICS, INC. Proceeds from Sale of Productive Assets
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Proceeds from Sale of Productive Assets of $35.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfProductiveAssets · last filed 2023-02-10
- ENLIVEN THERAPEUTICS, INC. proceeds from sale of productive assets for fiscal 2022 was $35.00M.
| Period end | Proceeds from Sale of Productive Assets | Proceeds from Sale of Productive Assets 12 month |
|---|---|---|
| 2022-12-31 | $35.00M 10-K · filed 2023-02-10 | |
| 2022-10-06 | $250.00M 10-Q · filed 2022-10-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |